NASDAQ
16.89USD
+0.12 (+0.72%)
We have scored 5 news catalysts on Crescent Biopharma, Inc. (CBIO) over the past 12 months. The biggest single-day move next to one of them came Sep 15, 2026, when CBIO closed −4.5%: “Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript”. Coverage across the window leans positive (average ticker sentiment +0.28). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
627.4M
P/E
—
EPS
—
Beta
1.23
52W range
8.72-27.41
Day range
16.15–17.87
Open
16.60
Prev close
16.77
Volume
3.1M
Avg volume
356.5K
Dividend
0.00
IPO
2014-01-10
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Crescent Biopharma, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for CBIO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
